12.3 Product Storage, Labelling and Excursion Response

Product Storage, Labelling and Excursion Response

ICH E8(R1) emphasises study objectives rather than a rigid sequence. Development activities can overlap; sample sizes, durations, populations and blinding are determined by the question and product. A rare-disease confirmatory study need not enrol thousands, and an early pharmacology study need not use healthy volunteers. Study phase is a useful descriptor, not permission to skip consent, ethics review or appropriate safety oversight.

Investigational Product Accountability, Handling & Storage

In clinical research, an Investigational Product (IP) is defined as a pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a clinical trial. Because investigational products have not yet received broad marketing authorization, their pharmacological profiles, physical stability limits, and toxicological risks require specialized handling protocols.

For the Clinical Research Associate (CRA), auditing pharmacy accountability logs, verifying storage conditions, investigating temperature excursions, and performing physical unit reconciliations are non-negotiable core monitoring duties.

The Investigational Product Lifecycle & Regulatory Labeling

Under ICH GCP, the investigational product lifecycle spans eight sequential stages:

Clinical Trial Packaging and Blinding

Investigational products should be packaged appropriately designed to prevent contamination, degradation, or premature unblinding during transit and storage. In double-blind studies, matching placebos or active comparators should use an appropriate masking strategy with controls against unintended disclosure.

Labelling and supply instructions

Labelling follows applicable requirements and should preserve product identification, correct use and the blind where relevant. Verify trial-specific identifiers, batch/serial or kit numbers, expiry when applicable, and storage/handling instructions. Do not assume every jurisdiction uses a US caution statement. Packaging should protect the product during handling and transport; requirements such as child resistance depend on the product and situation.

Storage Environmental Controls & Cold Chain Maintenance

Investigational products are chemically and biologically sensitive formulations. Maintaining the validated temperature range across the entire supply chain—from sponsor distribution depots to investigative site pharmacy refrigerators—is mandatory to prevent molecular degradation, protein denaturation, or toxic breakdown product formation.

Storage controls come from the product instructions

Use the sponsor's actual storage range, permitted handling time, transport requirements and stability information. Refrigeration at 2–8°C is an example for a specified product, not a universal investigational-product rule. Ambient, frozen and ultra-low conditions also vary by formulation. A CRA cannot clear an excursion from a generic temperature chart or by assuming a product that feels cold remains usable.

Monitoring devices, calibration, alarm response, backup arrangements and checking frequency should be appropriate to the product and agreed procedures. A generator is one possible continuity measure; a qualified backup storage location and a tested transfer process may be another. Establish who receives out-of-hours alerts and what happens when the first contact is unavailable. Review actual monitoring records and past excursions, not merely the presence of a thermometer.

Temperature Excursion Management Protocol

A Temperature Excursion occurs whenever the storage environment rises above or falls below the protocol-specified range for any duration of time. The CRA and site staff must execute a strict 5-step corrective response:

Chain of Custody & Accountability Documentation

Investigative sites must maintain meticulous, contemporaneous written documentation accounting for every single dosage unit received, stored, dispensed, and returned.

Product recalls and restricted trial activities

E6(R3) calls for investigational product supply after the required IRB/IEC and authority approvals/favourable opinion. The sponsor should have a retrieval process for deficient recalls, expired product and other authorised returns or disposition. A monitor verifies that the applicable instructions reach the site and become traceable action.

For a batch recall, identify the affected batch/kit numbers, quantities held and participant use. Protect affected stock from further dispensing, verify required retrieval or disposition and involve the investigator for participants already exposed. Preserve accountability and relevant communication; an inventory count alone does not establish that every affected participant was evaluated. Do not independently clear replacement product or restart restricted activity because replacement boxes arrived.

An authority or sponsor restriction may affect recruitment, a cohort, a product or particular procedures. Confirm its scope, notifications and participant-care plan, then verify site implementation. Resumption requires the appropriate clearance and readiness under the actual decision. Retain safety committee recommendations and the sponsor response as relevant while protecting unblinded information from people who should remain blinded.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1, ICH E8(R1), ACRP CCRA Exam Content Outline.